Microbicide clinical trial adherence: insights for introduction by Cynthia Woodsong et al.
Review article
Microbicide clinical trial adherence: insights for introduction
Cynthia Woodsong
§,1, Kathleen MacQueen
2, K Rivet Amico
3, Barbara Friedland
4, Mitzy Gafos
5, Leila Mansoor
6,
Elizabeth Tolley
2 and Sheena McCormack
5
§Corresponding author: C Woodsong, International Partnership for Microbicides, 8401 Colesville Rd. Ste 200, Silver Spring, MD 20910, USA.
(cwoodsong@ipmglobal.org)
Abstract
After two decades of microbicide clinical trials it remains uncertain if vaginally- delivered products will be clearly shown to
reduce the risk of HIV infection in women and girls. Furthermore, a microbicide product with demonstrated clinical efficacy must
be used correctly and consistently if it is to prevent infection. Information on adherence that can be gleaned from microbicide
trials is relevant for future microbicide safety and efficacy trials, pre-licensure implementation trials, Phase IV post-marketing
research, and microbicide introduction and delivery. Drawing primarily from data and experience that has emerged from the
large-scale microbicide efficacy trials completed to-date, the paper identifies six broad areas of adherence lessons learned: (1)
Adherence measurement in clinical trials, (2) Comprehension of use instructions/Instructions for use, (3) Unknown efficacy and
its effect on adherence/Messages regarding effectiveness, (4) Partner influence on use, (5) Retention and continuation and (6)
Generalizability of trial participants’ adherence behavior. Each is discussed, with examples provided from microbicide trials. For
each of these adherence topics, recommendations are provided for using trial findings to prepare for future microbicide safety
and efficacy trials, Phase IV post-marketing research, and microbicide introduction and delivery programs.
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Introduction
After two decades of clinical trials testing a wide array of
products and hoped-for protective mechanisms, the CAPRISA
004 trial provided evidence that a vaginal microbicide con-
taininganantiretroviral(ARV)(tenofovir)couldprotectagainst
sexual transmission of HIV [1]. It is still an open question
whether the findings regarding the effectiveness of coitally
associated tenofovir gel use will be confirmed. However,
increasing evidence supporting the potential efficacy of
vaginally delivered antiretrovirals has stimulated interest in
what will be required to most efficiently introduce effective
products. Such products will fill an important need for women
and girls, who accounted for an estimated 1.2 million of
the world’s new HIV infections in 2011 and who often have
limited ability to negotiate for their personal protection with
their partners [2].
A microbicide product with demonstrated clinical efficacy
will only be effective if it is used correctly and consistently.
Evidence about factors that will likely influence uptake as
well as correct and consistent use of vaginal microbicide
products proven to be effective is included in the data
collected in microbicide clinical trials, as well as ancillary
social and behavioural science research. To date, scientific
discourse regarding study-product adherence in clinical trials
has largely centred on motivating adherence to support the
primary objective of the trial and the accuracy of measure-
ment to aid interpretation of results. For the introduction of
effective microbicide products into real-world communities
(which we refer to here as ‘‘microbicide introduction’’), the
emphasis shifts to measuring uptake, and the interest in
adherence is to support individuals to reduce their risk by
achieving correct and consistent use. Information on adher-
ence that can be gleaned from microbicide trials is relevant
for future microbicide safety and efficacy trials, pre-licensure
implementation trials, Phase IV post-marketing research, and
microbicide introduction and delivery. This article reviews
such information and assesses the implications for micro-
bicide introduction, drawing upon the adherence information
primarily from the large safety and efficacy microbicide trials
completed to-date. Since topical vaginal products have been
the most intensely studied (compared to rectal products),
lessons learned from these trials predominate, and our focus
is on vaginal microbicide use.
Background
Adherence in microbicide trials
Adherence considerations in microbicide trials can be con-
ceptualized in three broad areas: (1) achieving correct and
consistent product use, (2) measuring product use and (3)
ensuring visit completion and trial retention. Difficulties in
measuring adherence in microbicide trials have been widely
observed and well-documented [37]. Adherence is framed,
defined and measured almost exclusively as a modifier of
product efficacy [8,9]. The search for an objective measure
of adherence as an effect modifier is constrained by the
limitations of self-report and biological markers. Self-reported
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1adherence data are prone to error due to participants
intentionally or unintentionally misreporting use, staff errors
in data collection and lack of clarity about what is being
measured. Biological markers are limited by the cross-
sectional time-frame for a given measurement, practical
constraints on collection of random unannounced speci-
mens, the likelihood of more adherent product use prior
to scheduled clinic visits and difficulties of measuring some
drugs that are not systemically absorbed [4]. In spite of these
challenges, some trials have reported increased efficacy
correlated with defined levels of adherence [1,10]. The use
of composite measures or triangulated indicators has proven
especially useful [11]. For example in the CAPRISA 004
tenofovir gel trial, the relationship between adherence and
effectiveness was assessed using a composite measure based
on self-reported sexual activity and used applicator counts
combined with an assessment of cervico-vaginal fluid drug
levels [1].
Counselling approaches adopted in recent HIV prevention
trials have shown some promise for improvements in
counselling to increase adherence [12]. These have drawn on
demonstrated success in achieving ARV treatment (ART)
adherence [1315] and other risk reduction programs. How-
ever, little evidence is available regarding the impact of these
approaches on the use of products in the context of a
microbicide trial, where participants are blinded to whether
theyareusingtheactivetestproductoraplacebo.Behavioural
modelsforpre-exposureprophylaxisadherencehaveemerged
[12,16,17], but evaluation of the utility of these models is
needed. Moreover, since no single adherence counselling
approach will work for all contexts, specific incorporation of
socio-cultural factors should be part of anyexplanatory model
or proposed intervention approach [17,18]. For example, the
gender dynamics and socio-cultural norms influencing beha-
viour of heterosexual couples in sub-Saharan Africa may
preclude the type of adherence negotiation indicated by a
model based on United States norms.
A high rate of visit completion and high retention are
considered critical components for achieving adherence in
microbicide trials; participants who miss visits also miss
the opportunity to refill product, which may result in non-
adherence or non-persistent use, and ultimately can under-
mine the accuracy of efficacy estimates. Additionally, those
who miss visits or who are lost to follow-up negatively impact
the overall ability of the trial to determine product efficacy.
However, it is important to note that the very high rates of
retention in studies do not appear to ensure high rates of
actual product use. Thus, trial retention is a necessary, but
insufficient, condition for consistent product use. Further,
the ability of trials to retain participants for periods of one
to three years may not be indicative of product continuation
rates for similar periods of time. Generalizability depends on
the extent to which factors driving trial retention are similar
to factors that will influence continuation and persistent use
of product outside of a trial setting.
Microbicide trial experiences
A variety of adherence lessons and associated recommenda-
tions that arise from these lessons are summarized in Table 1.
Table 2 provides a brief overview of the trials from which
these lessons have been learned. Below, we discuss each
major area, drawing examples from the trials.
Adherence measurement in clinical trials
Accurate measurement of product use has been challenging,
with most trials observing that microbicide adherence is
over-estimated by product count or self-reported measures
[10,24]. Understanding the reasons for over-reporting can
nonetheless provide valuable insights. Counselling provided
in the early microbicide trials emphasized a goal of 100%
adherence, which may have contributed to a social desir-
ability bias to over-report. ‘‘Person-centred’’ approaches that
focus on what is reasonable and actionable for participants
have been adopted in more recent trials and have shown
some promise [1,12]. Although social desirability is a key
underlying factor, the wording of questions may discourage
a negative response and added procedures in response
to reports of non-adherence may influence future reporting
behaviours. For example, if participants soon learn that
reporting non-adherence results in a longer clinic visit, they
may be less inclined to report non-adherence at subsequent
visits. Several of these concerns have been commonly
reported with regard to measuring ART adherence as well,
leading to recommendations for short or manageable recall
periods, clear and neutral wording of adherence questions
and incorporation of a permission statement or acknow-
ledgement that it is not uncommon to miss ‘‘doses’’ on
occasion [25,26].
Adherence measurement will be needed for future trials,
including Phase IVs, as well as for service delivery indicators.
For ARV-based microbicides, drug levels combined with self-
report may be necessary tools for assessing adherence during
early roll-out. However, over time, less emphasis should be
placed on these measures and more on other outcomes (e.g.
uptake, retention in the program, HIV breakthrough infections
and incidence, HIV resistance) for assessing program success.
Intensive or expensive objective measures of adherence
will likely become increasingly less feasible and good proxy
measures of high adherence predictive of decreases in HIV
incidence will be needed. In that context, adherence meas-
ures that were too statistically ‘‘noisy’’ for trial purposes may
in fact be useful for programmatic monitoring and evalua-
tion purposes. For example, it may be adequate to deter-
mine whether adherence exceeds a critical threshold value
for effectiveness rather than estimating an exact level of
adherence.
Comprehension of microbicide use-instructions
The products tested in microbicide trials have required either
daily/continuous use, or coitally associated use. Microbicide
trials tend to provide product use-instructions that include
culturally appropriate pictorial diagrams rather than the text-
heavy printed instructions that are typical of package inserts
in developed-countries. Clinical trial participants are provided
with regular education and counselling about use require-
ments and have access to knowledgeable health professionals
to answer questions about use. However, trials have none-
theless observed numerous erroneous beliefs about how to
correctly use microbicides. Some trial participants came to
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2Table 1. Lessons learned from microbicide trial adherence experiences, and recommendations for future delivery programs, trials
and research
Lessons learned from microbicide trials
Recommendations for future delivery programs, trials,
operations research and implementation research
1. Adherence measurement
  Self-reported adherence appeared exaggerated in all
trials Biological markers of adherence reveal much lower
levels of adherence.
  Triangulation of data offers the opportunity to probe and
understand inconsistencies in self-report.
  Over-reporting may be due to social desirability bias.
Bias may be introduced by the way the questions are
worded, or the summary measures used for reporting
adherence.
  Over- and under-reporting may be due to forgetfulness
or inaccurate recording by staff.
  Counselling for correct and consistent use should build on behaviour change
best practices to improve adherence reporting in trials and continued use of
effective products. Evaluation of counselling will also be needed.
  Acknowledging that 100% use is unrealistic for some women may improve
accuracy of self-report.
  Triangulation of multiple measures should improve accuracy of adherence
measurement.
  Prescribers and those supporting adherence must be well trained to listen
and appropriately encourage accurate reporting of product use.
  Outcome based measures of adherence (such as HIV infection) will be
relevant for microbicide service delivery.
2. Comprehension of use-instructions
  Trials have observed that some women misunderstood
instructions on how to correctly use microbicides.
  The use of locally appropriate illustrated materials has
facilitated counselling about correct product use.
  Participants who are anxious about use generally
overcome their concerns.
  Women may be reluctant to use microbicides during
menses.
  Social marketing research is needed to develop instructions for users and
counselling messages for dispensing staff. These messages should be
evaluated.
  Service provider training will be required for introduction of this new class
of product. Initial counselling about use should acknowledge common
concerns and provide reassuring evidence-based information on how others
have overcome similar concerns.
  Guidance on use during menses is needed.
  For continuous-use methods, information is needed on how quickly a
protective effect can be achieved after product use is initiated or re-initiated
since some women will discontinue or disrupt use during menses.
3. Unknown efficacy and its effect on use-adherence
  Not all participants and staff believe the message of
uncertain efficacy, even though they understand it.
  Participants may believe that a placebo gel ‘‘protects’’
them because the lubrication provided makes sex more
comfortable (‘‘safe’’).
  Communication about unknown level of efficacy,
targeted efficacy and lack of placebo efficacy has been
misinterpreted by some participants and clinic staff.
  Messages about unknown efficacy are qualitatively different than messages
about partial efficacy, and thus comprehension of partial efficacy must be
studied and effective communication strategies developed.
  It will be important to monitor risk behaviour, and biological markers of risk
such as sexually transmitted infections in case there is a decrease in
condom use once a product is known to be effective.
  Users need information on contraceptive effect and effect on male partner
since in the absence of such information, incorrect assumptions about
protective effects could increase risk of infection and/or unintended
pregnancy.
4. Partner influence on use
  Type and nature of sexual relationship is likely to
influence use.
  There is considerable variability in frequency of sexual
intercourse amongst participants and over time.
  User’s experiences and expectations for microbicides’
impact on sexual pleasure for themselves and their
partner will influence use.
  Willingness or intention to discuss and/or disclose use is
associated with partner type.
  Counselling for users should include consideration of partner type and
sexual frequency, with counselling messages for use-strategies tailored to
these variations.
  Relationships and associated risk change over time and thus protection
needs will change over time. Users’ relationships and needs should be
periodically assessed.
  Messages about microbicide effects on men’s and women’s sexual pleasure
should be crafted in accordance with local norms.
  Messages about the potential for covert use should include consideration
of partner type and the potential for negative consequences if use is
discovered.
5. Retention and continuation
  Retention in clinical trials has been high over 12 years,
but it is unclear what this portends for continuation in
non-trial settings when women are not reimbursed,
yet know they are receiving an effective product.
  Quarterly visits for re-supply appear to be feasible, at least with initial
introduction, but should be integrated with other services.
  Reasons for product discontinuation should be explicitly considered and
appropriate counselling developed, including pregnancy, breastfeeding and
life circumstances that could result in reduced HIV risk for a woman.
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3their own conclusions about how to correctly use the vaginal
products, and these practices could be harmful and/or reduce
efficacy. For example, anecdotal information from the HPTN
035 microbicide trial of coital use of PRO 2000 gel suggested
that some women erroneously thought that the gel applicator
needed to be inserted very high into the vagina, thereby
creating the potential for physical damage to the cervix.There
were also anecdotal reports that some women thought
the gel needed to get washed out of the vagina after sex. In
the Carraguard Phase 3 trial, and the MDP301 Pilot, some
women misinterpreted the instruction to insert gel up to
1 hour prior to sex to mean that they had to wait an hour
after inserting the gel before having sex. Information about
the need for condom use along with the microbicide has
provided additional confusion and uncertainty about micro-
bicide products. In the absence of correct understanding of
the information given, trial participants as well as future users
will reach their own conclusions when interpreting use-
instructions. This underscores the importance of conducting
pilot studies in advance of product introduction, as well as
evaluations with early introduction programs, to ensure that
the information is presented clearly and correctly understood
by intended microbicide users.
A number of microbicide trials have documented the
newly enrolled participants’ expectations about microbicides
prior to their initial use and how these pre-use expectations
compare to use-experience. Trials have generally reported
that products were either better than or similar to what was
expected and comfort with use appears to increase during
the trials. The pre-use expectations documented in micro-
bicide trials may be similar to those of future new ‘‘con-
sumers’’, as they likely reflect cultural and community norms
for sexual behaviour and practices. The expectations and
post-use experiences of trial participants could be infor-
mative for development of use-counselling messages and
package inserts.
Minimal attention has been given to the impact of men-
struation on microbicide use-adherence, with scant findings
reported in the literature [27]. Recent microbicide trials
generally require participants to be using effective contra-
ceptive methods while in the study, and contraceptive-related
amenorrhea is quite common. Nevertheless, since most
Table 1 (Continued)
Lessons learned from microbicide trials
Recommendations for future delivery programs, trials,
operations research and implementation research
  Retention does not necessarily predict continuation of
product use, with evidence suggesting that product use
during trials may decrease over time despite re-supply
during study visits.
  Despite requirements for contraceptive use, and
counselling to avoid pregnancy, many trial participants
have been taken off product due to pregnancies.
  Women value counselling, HIV testing and other services
provided in trial settings.
  Some participants, partners and communities are
concerned about blood testing, including the
volume of blood taken, frequency, and
dispensation of samples.
  Requirements for refills should be streamlined and additional services made
available at refill locations. Transportation vouchers or other benefits could
incentivize consistent use at early stages of microbicide introduction.
  Periodic reassessment of women’s needs, and consultation about changes
in risk should be done to maximize continuation.
  Women need clear information about when and why to discontinue use
(e.g. during pregnancy) and to seek medical advice for continued use.
  Provision of additional services (at least counselling) may improve
willingness to access re-supply services. Access points providing re-supply
only (e.g. between quarterly clinic visits) may be sufficient for some users
and some products. The type of counselling most effective in a given
population requires targeted study.
  Research is needed to inform the minimal frequency and type of HIV testing
that is necessary for ARV-based products, and this minimum should be
required for service delivery.
  Continued community engagement is essential to address and monitor
concerns about microbicide products.
6. Generalizability of trial participants’adherence behaviour
  Women in a range of socio-cultural settings and at high
risk of infection find vaginal microbicides to be
acceptable and easy to use.
  Women may not consider themselves to be at risk even
in countries where HIV is prevalent.
  Some important population groups have not been
included in clinical trials.
  Microbicide trials have been conducted primarily in East
and Southern Africa, followed by sites in India, United
States, West Africa and Thailand.
  Studies are needed for populations who have not been well represented in
microbicide trials to-date (specifically, adolescent women, pregnant
women, older women) to assess potential additional contextual issues that
may influence uptake, adherence and continuation.
  Programs should include counselling to help women assess their risk.
This could potentially motivate adherence.
  Secondary analyses of clinical trial data should be explored, stratified by
variables such as age, risk, etc., to determine possible correlates of
adherence and continuation of use.
  Research will be needed in regions of the world where microbicide trials
have not concentrated since sexual behaviours and norms likely to
influence adherence may differ.
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4women menstruate at some points in their sexually active
lives, the potential menses-related adherence issues must
be considered. In sub-Saharan Africa, evidence from multiple
cultural contexts suggests that sexual activity tapers during
menses [2830]; thus, in many settings adherence during
menses may be a non-issue for coitally dependent methods.
For those who have sex during menses, the combination of
microbicide gel products and menstrual flow might cause
excessive leakage, or make the vagina too lubricated and
adherence might drop. The HPTN 059 Phase II study of
tenofovir gel, conducted in India and the U.S., reported that
menses was given as the main reason for non-adherence [31].
Microbicides requiring continuous use may be discontinued
during menses, and not resumed in time for adequate pro-
tective drug levels to be reached.
Unknown efficacy and its effect on use-adherence
The effect of unknown efficacy of microbicide trial products
has multiple dimensions. Trial participants are told and
regularly reminded that the ‘‘active’’ product may not protect
them; that they may have been assigned to use a placebo;
and that while the ‘‘active’’ product has unknown protec-
tive benefits, it may also have unknown adverse effects.
Nevertheless, some trial participants in the HPTN 035 trial
(and their partners) believed that both partners were pro-
tected by a study product in a placebo-controlled, blinded
trial [32]. A proven effective product will certainly be less
than 100% effective, and it can be expected that users
may over-estimate the protection provided and/or assume a
‘‘forgiveness factor’’ that can accommodate inconsistent use.
However, the concept of partial efficacy can be difficult to
explain to policy makers, community workers and poten-
tial microbicide users. Future users may erroneously calculate
what partial efficacy means, and think in terms of additive
effects (e.g. if microbicide is 40% effective and male circum-
cision is 60% effective, microbicide use with a circumcised
partner provides 100% protection; or, a woman using a 40%
effective microbicide who believes there is a 5050 chance
her partner is HIV, may believe she has a 90% level of
protection).
Future users and those advising on use will need clear
information about levels of and requirements for protection.
Although to-date, vaginally delivered ARVs have been shown
to be effective in protecting only women, not the male
partner [1], an erroneous assumption of protection for both
partners could contribute to male partner discontinuation of
Table 2. Overview of Microbicide Clinical Trials
Clinical trial General description Population description
Method for recoding adherence;
adherence rate; trends noticed Retention rate (%)
Col 1492 N-9; Phase
III [19]
a,e,f
Vaginal gel (pre-coital);
n765; 48 weeks;
1-monthly visits
Age: 16; 100% Sex workers Self-report: difference by partner
type, high self-reported use
68
HPTN 035; Phase IIb
[20]
a,b,c,d
Vaginal gel (pre-coital),
n3,099; 1230
months (av. 20);
1-monthly visits
Age: 1856 (but few above age
45); 62% married
Self-report: 81% last sex acts 94
Population Council
Carraguard;
Phase III [21]
a
Vaginal gel (pre-coital);
n6,202; 924
months; 3-monthly
visits
Age: 16; 63% single/never
married; 31% married/living as
married
Self-report: 96% of women reported
using gel at last sex act; applicator
dye test: gel used in 42% of sex acts,
overall
69
CONRAD Cellulose
Sulfate; Phase III
[22]
a,b,c,e
Vaginal gel (pre-coital);
n1,398; 12 months;
1-monthly visits
Age: 18; 23% married; 3
partners previous 3 months
Self-report: 87% overall, 46% use
when condoms not; lower use with
primary partners
Study stopped early
MDP 301 PRO2000/
5; Phase III [23]
a,b
Vaginal gel (pre-coital);
n9,385; 12 months
(24 in Uganda);
1 monthly visits
Age: 16; Sexually active but
less than 14 acts per week;
99% in stable relationships
Self-report and used/unused
applicator count: 89% last sex act;
56% last sex act at every visit
88
CAPRISA 004
Tenofovir; Phase
IIb [1]
a
Vaginal gel (pre- and
post-coital); n889; 30
months; 1-monthly
visits
Age: 1840; mean 23.9;95.1;
Sexually active with at least
2 vaginal sex events in previous
30 days; 95% with one stable
partner in previous year; 12.3%
living with regular partner;
2% ever received money in
exchange for sex
Self-report and used and unused
applicator return (sub-samples:
method developed to confirm if used
applicator returned was in fact used;
‘‘wise-bag’’ to determine when
applicator removed); 18-month
decrease in efficacy may be due to
adherence drop due to trial fatigue
95
Trial sites:
aSouthern Africa,
bEast Africa,
cIndia,
dUnited States,
eWest Africa and
fThailand.
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5condom use. Women who use ARV-based products will have
regular HIV tests confirming that they are not infected.
However, infection may occur between HIV tests and partners
of women using microbicides may over-estimate the like-
lihood that their partner must be HIV negative. Furthermore,
since the first microbicide products will likely be recom-
mended for the protection of women only, men may be
reluctant to support use.
Participants and health professionals may also assume
that microbicides have a contraceptive effect, thinking that
the product inactivates or ‘‘kills’’ everything associated with
an ejaculate. Although health professionals may be unlikely
to recommend a woman discontinue use of a highly effective
contraceptive method, future microbicide users may reach
their own conclusions and inappropriately use a microbicide
for dual purposes. A number of products are in development
with the goal of providing combined contraception and HIV
protection; thus, care must be taken to avoid confusion
about the potential array of products.This will be particularly
true when introducing an HIV preventive vaginal ring in
settings where contraceptive vaginal rings are available. If a
microbicide is erroneously assumed to be contraceptive,
this could increase adherence, yet contribute to unintended
pregnancies.
Partner influences on use
Evidence from microbicide trials strongly indicates that the
decision to use microbicides and the ability to use them
correctly and consistently will likely be influenced by the
aspects of women’s sexual relationships [3337]. Although
microbicides have long been heralded as a potential method
for women to use without their partner’s active involvement,
cooperation or knowledge, the realities of using a micro-
bicide in secrecy or without potential for partners to notice
may create a high burden and challenge adherence. Early
microbicide trials indicated that women generally told their
partners about trial participation for a variety of reasons:
some women considered that lengthy trial participation with
regular visits would be hard to keep secret, some felt it was
wrong to not tell a partner in a committed relationship (e.g.
husband) or felt that a decision like this should be made as a
couple, some were afraid of the consequences of being
discovered, and concerns were expressed about microbicides
negatively impacting the partner’s sexual pleasure [38,39]. As
awareness of these issues accumulated among the micro-
bicide research community, many trials encouraged women
to consider telling their partner, because it was felt that
partner support could improve adherence and reduce the
potential for social harms.
When effective microbicides are introduced, some women
will likely achieve higher adherence with partner support,
some may be highly motivated to use products discretely,
and some may consider that use and disclosure are their own
decisions, regardless of the partner’s views.The ability to use
discretely may vary by product type and use-regimen. Trial
evidence indicates that women may be more likely to use
microbicides without disclosure to casual or paying partners
than with long-term steady partners, and adherence rates
have been observed to differ according to partner type
[22,40].
Retention and continuation
Microbicide trials include active outreach, reimbursements
and care referrals to help achieve the high retention needed
to support a valid result. Continuation of use, rather than
‘‘retention’’, is the relevant concern for microbicide delivery,
and this concept has somewhat different aspects for con-
sideration. Clinical trials have achieved high retention rates
(Table 2). However, future users will not be reimbursed for
the costs associated with visiting the refill source, and they
may not receive the additional services or reminders to
return that are currently used in clinical trials. How HIV
testing requirements, which have been monthly to-date in
the ARV microbicide trials, will impact willingness to continue
use will be difficult to predict since some women consider
regular testing to be a benefit of microbicide trial participa-
tion, while others dislike it because of fears about blood
testing, in general, and the potential for a positive result.
Once the reimbursement, transport support and out-
reach efforts of clinical trials are removed, women may
have difficulty accessing microbicides to maintain correct and
consistent use. Microbicides will be a new class of product,
and it is not clear as to the service delivery setting in which
they will be provided. The type of access needed will vary
by the type of product and re-supply schedule. Current
products under evaluation range from a single vaginal ring
used continuously for at least a month at a time, to boxes
containing a dozen or more pre-filled gel applicators for
coitally associated use. Depending on where service delivery
is situated, service providers may be overwhelmed and
confused by yet another service to deliver, and they will
likely have fewer resources and less time to spend with
women than what was provided in trials. As with use of other
health services, continued use will likely be influenced by
the way women are treated by providers. There are likely
to be significant differences between the clinical research
environment and typical health service settings, ranging from
amenities (e.g. refreshments, available seating) to staffing
(e.g. ratio of staff to clients, workload, salary) to time spent
at the facility (e.g. waiting in general waiting rooms).
Some microbicide trials have observed trends in decreased
adherence over time. Decreased adherence may be due in
part to fatigue with clinical trial requirements combined with
a product of uncertain benefit. Nonetheless, similar trends
may be observed with use of microbicides proven effective,
as has been seen with contraceptives. Women’s needs for
protection will not remain constant over time. A change in
partner, or a change in the partner’s risk factors, could
influence the real and perceived need for continued use
of a microbicide, or type of microbicide. Given that women
will make their own assessments of the relative risks of
sexual behaviours (e.g. concurrent or serial multiple part-
ners), efforts to help women to evaluate and periodically
re-evaluate their risks will be needed [41,42].
The clinical requirements of microbicide trial participation
have often benefitted the health of the trial participants,
but they are also burdensome and complex. Microbicide
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6trials require monthly or quarterly clinic visits that include
physical check-ups, collection of blood and urine specimens,
gynaecological exams, and sexually transmitted infections
and pregnancy testing. Clinical requirements in the context of
microbicide introduction are likely to be much less demand-
ing, which could improve continuation.
To date, microbicide trial participants have been coun-
selled to avoid pregnancy since the potential effects of the
investigational drug on a foetus are unknown. Increasingly,
eligibility criteria for trials include use of an effective contra-
ceptive method and stated willingness to avoid pregnancy for
the trial duration. Nevertheless, high pregnancy rates have
been observed in many of the microbicide trials [7,43,44].
If refill schedules for effective microbicides are quarterly, or
longer, some women using microbicides will become preg-
nant. Until studies have demonstrated the safety of micro-
bicides for the foetus, contraceptive counselling messages
must also be stressed when microbicides are prescribed, and
guidance provided on the need to stop product use as soon as
pregnancy occurs and contact their health care provider.
Generalizability of trial participants’ adherence behaviour
To date, more than 20,000 women have participated in
large-scale advanced microbicide trials globally (Table 2).
Trial participants in the large trials have tended to be in their
20s30s, with a main partner (e.g. husband) in some trials, or
engaged in sex work in others. Participants are typically
considered at risk of HIV infection because they reside in high
incidence locations, and/or they have multiple sex partners
or partners who are migrant workers. Targeting such popula-
tions is necessary to determine the safety and efficacy of
products in women who are representative of those who
could benefit the most from using effective microbicides.
However, they may not be representative of those who will
actually do so. Being at risk in terms of community pre-
valence of HIV or risk behaviour patterns may not confer
‘‘feeling’’or believing oneself to be at heightened risk for HIV
[4,45]. Individuals’ self-perception of HIV risk varies within
trial populations, and the link between risk perception and
consistent product use or retention in trials has not been well
established to-date.
Although risk perception as a motivator for adherence in
placebo-controlled, blinded clinical trials is not well-known,
once an effective product is available, it is highly likely that
the women accessing it will perceive themselves to be at risk
of HIV. Therefore, it will be important to link supply services
to populations at actual high risk by raising awareness of
their risk and the availability of microbicides as an HIV
prevention strategy. The inclusion of effective microbicides
could be a positive new program element in behavioural risk
reduction programs. When effective microbicides are made
available to women who need them and believe they need
them, adherence could be higher than what has been
actually achieved in trials.
Some key groups of women have been largely excluded
from microbicide efficacy trial participation for ethical and
practical reasons, and their sexual and/or health-seeking
behaviour may differ in important ways from women who
have participated in microbicide trials. These groups include
adolescents younger than 16, migrants, older women and
pregnant women. There are also women with medical issues
that usually preclude trial participation (e.g. latex allergy,
genital abnormalities). Women who do not access formal
health care services may also have different needs.
Discussion
Itislikelythatwomen’sneedsformicrobicideswillbebestmet
if multiple types of products with varying use requirements
are available. Some women will prefer a coitally dependent
method,somewillpreferacontinuous-use method,andthese
needs will change across a woman’s sexual life [4648].
Future adherence to an effective microbicide may exceed
the levels achieved in trials since trial participants were
repeatedly reminded of the unproven efficacy of products
and the randomization to active or placebo arm. Women
were also enrolled into trials regardless of their perceived
level of personal risk. Alternatively, when the content and
frequency of adherence counselling are strained by limited
resources typical of service delivery environments, adherence
and continuation rates could suffer.
When microbicides are introduced, service delivery pro-
grams will focus on achieving uptake and continued use over
a sufficient period of time to demonstrate a positive public
health impact. Important knowledge has been gained from
microbicide clinical trials about factors that are associated
with inconsistent use of microbicide products (as well as HIV
risk factors). These insights are invaluable for the develop-
ment of microbicide promotion strategies and targeted
counselling for those that need more support.
This article has not focused on clinical trial findings
pertaining to microbicide acceptability [49,50]. It is often
conjectured that high acceptability supports high adherence,
but clinical trial participants are asked to adhere to product
use as a study requirement, not because they find the
product acceptable. High acceptability also does not neces-
sarily correlate with high willingness to use [51] and, thus,
cannot reliably predict future uptake [52]. However, trial
participants will probably not be adherent users of a product
that they find clearly unacceptable, and those who say they
are unwilling to use a product probably will not use it once
it is available on the market. Conversely, factors that have
been associated with acceptability in clinical trials, such as
improved sexual pleasure (for either or both partners)
[53,54], could be incorporated into messaging for microbicide
introduction.
Many of the adherence issues presented here are not
directly associated with the objectives of microbicide clinical
trials. Thus, although relevant data may be housed in trial
datasets, they may not have been analyzed to investigate
the social and behavioural adherence implications raised
here since they were not required for primary or secondary
analyses. Further, when no reduction in HIV was observed,
there was often little incentive to conduct further analyses.
These data should be analyzed for potential contributions to
better understanding the use factors outlined in this article.
Secondary or meta-analyses could provide important infor-
mation for those developing programs, counselling messages,
use-instructions and social marketing campaigns. Clinical trial
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use, and advice to future consumers about when to seek
medical attention and/or discontinue use.
Women in clinical trials are told ‘‘we don’t know if it
works’’, which is a very different message than ‘‘we know it
works if you use it in this way’’. The social and beha-
vioural science data collected within microbicide clinical
trials cannot provide clear indicators of behaviour to reliably
predict use-behaviour of an approved product in non-trial
settings. Nevertheless, a number of trials have adopted
‘‘motivational’’ and ‘‘person-centred’’ counselling to support
or improve adherence, and we can expect an increasing body
of evidence about the potential for such approaches to
strengthen correct, consistent and continued microbicide
use. Some of the adherence challenges that trial participants
face highlight larger issues of gender inequality. The intro-
duction of effective microbicides, and appropriate counsel-
ling on how to use them correctly and consistently, could
create inroads for women’s empowerment while reducing
their risk of HIV infection.
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